BioCryst Pharmaceuticals, Inc. (BCRX) announced new insights from an analysis of U.S. claims data regarding patients with hereditary angioedema (HAE) on Monday. The findings reveal that following the initiation of treatment with Orladeyo, there was a significant decrease in healthcare resource utilization among HAE patients. This includes a reduction in hospitalizations, emergency room visits, and the use of on-demand therapies. The analysis is set to be presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024 national meeting, occurring in Las Vegas from October 14-17.
"Our analysis of the claims data extends previous research suggesting that Orladeyo not only positively affects the lives of individuals suffering from HAE but also benefits the broader healthcare system," stated Sandra Christiansen, Professor of Medicine and Director of Translational Research at the US HAEA Angioedema Center, University of California, San Diego. "Our investigation offers compelling real-world evidence that underscores Orladeyo's clinical and financial value as a preventive therapy for HAE."
